Early Elevated IFNα Identified as the Key Mediator of HIV Pathogenesis and its low level a Hallmark of Elite Controllers.


Journal

Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035

Informations de publication

Date de publication:
11 May 2023
Historique:
pubmed: 22 5 2023
medline: 22 5 2023
entrez: 22 5 2023
Statut: epublish

Résumé

Advances in HIV therapy came from understanding its replication. Further progress toward "functional cure" -no therapy needed as found in Elite Controllers (EC)- may come from insights in pathogenesis and avoidance by EC. Here we show that all immune cells from HIV-infected persons are impaired in non-EC, but not in EC. Since HIV infects few cell types, these results suggest an additional mediator of pathogenesis. We identify that mediator as elevated pathogenic IFNα, controlled by EC likely by their preserved potent NK-cells and later by other killer cells. Since the earliest days of infection predict outcome genetic or chance events must be key to EC, and since we found no unique immune parameter at the onset, we suggest a chance infection with a lower HIV inoculum. These results offer an additional approach toward functional cure: a judicious targeting of IFNα for all non-EC patients.

Identifiants

pubmed: 37215045
doi: 10.21203/rs.3.rs-2813601/v1
pmc: PMC10197726
pii:
doi:

Types de publication

Preprint

Langues

eng

Auteurs

Hélène Le Buanec (H)

Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.

Valérie Schiavon (V)

Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.

Marine Merandet (M)

Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.

Alexandre How-Kit (A)

Laboratory for Genomics Foundation Jean Dausset-CEPH; Paris France.

David Bergerat (D)

Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.

Céline Fombellida-Lopez (C)

Laboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege; 4000 Liege, Belgium.

Armand Bensussan (A)

Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.

Jean-David Bouaziz (JD)

Université de Paris; INSERM U976, HIPI Unit, Institut de Recherche Saint-Louis, F-75010 Paris, France.
Dermatology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Arsène Burny (A)

Laboratory of Molecular Biology, Gembloux Agrobiotech,University of Liège; Belgium.
Global Virus Network, Baltimore, MD 21201, USA.

Gilles Darcis (G)

Laboratory of Infectious Diseases, GIGA-I3, GIGA-Institute University of Liege; 4000 Liege, Belgium.

Hongshuo Song (H)

Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.

Mohammad M Sajadi (MM)

Global Virus Network, Baltimore, MD 21201, USA.
Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.

Shyamasundaran Kottilil (S)

Global Virus Network, Baltimore, MD 21201, USA.
Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.
University of Maryland School of Medicine; Baltimore, MD 21201, USA, Program in Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD 21201, USA.

Robert C Gallo (RC)

Global Virus Network, Baltimore, MD 21201, USA.
Institute of Human Virology, School of Medicine, University of Maryland; Baltimore MD, 21201, USA, Department of Medicine, School of Medicine, University of Maryland, Baltimore, MD, 21201, USA.

Daniel Zagury (D)

21CBIO; Paris France.

Classifications MeSH